/term/ebit/STC:TRA Traphaco JSC (STC:TRA) EBIT
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Traphaco JSC (STC:TRA) » Definitions » EBIT

Traphaco JSC (STC:TRA) EBIT : ₫341,456 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Traphaco JSC EBIT?

Traphaco JSC's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₫76,812 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₫341,456 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Traphaco JSC's annualized ROC % for the quarter that ended in Mar. 2024 was 20.78%. Traphaco JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 37.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Traphaco JSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 11.75%.


Traphaco JSC EBIT Historical Data

The historical data trend for Traphaco JSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traphaco JSC EBIT Chart

Traphaco JSC Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 232,602.81 278,091.59 336,143.28 369,543.85 364,607.76

Traphaco JSC Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100,675.53 98,995.58 90,459.00 75,188.50 76,812.43

Competitive Comparison of Traphaco JSC's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Traphaco JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traphaco JSC's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Traphaco JSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Traphaco JSC's EV-to-EBIT falls into.



Traphaco JSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫341,456 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traphaco JSC  (STC:TRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Traphaco JSC's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=272273.252 * ( 1 - 20.92% )/( (972629.999 + 1099858.541)/ 2 )
=215313.6876816/1036244.27
=20.78 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2123900.644 - 369157.143 - ( 782113.502 - max(0, 634845.857 - 1530494.507+782113.502))
=972629.999

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1973272.577 - 295057.347 - ( 578356.689 - max(0, 513817.588 - 1412723.07+578356.689))
=1099858.541

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Traphaco JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=307249.716/( ( (463039.674 + max(272014.862, 0)) + (444356.776 + max(441976.213, 0)) )/ 2 )
=307249.716/( ( 735054.536 + 886332.989 )/ 2 )
=307249.716/810693.7625
=37.90 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(216114.817 + 467898.029 + 54880.117) - (369157.143 + 0 + 97720.958)
=272014.862

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(249249.094 + 489557.524 + 89958.376) - (295057.347 + 0 + 91731.434)
=441976.213

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Traphaco JSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=341455.514/2906165.858
=11.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traphaco JSC EBIT Related Terms

Thank you for viewing the detailed overview of Traphaco JSC's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Traphaco JSC (STC:TRA) Business Description

Traded in Other Exchanges
N/A
Address
75 Yen Ninh Street, Ba Dinh District, Ha Noi City, VNM
Traphaco JSC is engaged in the manufacturing and trading of pharmaceutical products, chemicals and medical supplies and equipment. The company's products include abfuco; amorvita multi; ampelop; aspirin; cagu and amongst others.

Traphaco JSC (STC:TRA) Headlines

No Headlines